ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
Want to see ALXO full AI Analyst Report?
ALXO Stock Chart & Stats
$1.67
$0.01(0.54%)
At close: 4:00 PM EST
$1.67
$0.01(0.54%)
Day’s Range― - ―
52-Week Range$0.40 - $2.66
Previous CloseN/A
Volume579.15K
Average Volume (3M)670.12K
Market Cap
$211.26M
Enterprise Value$228.60M
Total Cash (Recent Filing)$140.32M
Total Debt (Recent Filing)$5.22M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding134,562,910
10 Day Avg. Volume555,214
30 Day Avg. Volume670,121
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.52K
Enterprise Value/Ebitda-2.60
Forecast
1Y Price Target
$4.75Price Target Upside184.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker Strategy And Partner InterestBiomarker analyses showed stronger efficacy signals in patients with high CD47 when evorpacept was combined with HER2-targeted therapies, and a partner advancing a randomized study signals external confidence and may enhance targeted patient selection.
Drug Design And SafetyALX2004 was engineered to bind a different EGFR epitope using a novel linker and proprietary payload, and early dose escalation reported no dose-limiting toxicities, suggesting a potentially cleaner safety and improved potency profile.
Trial Design And Registrational PlanningThe ASPEN-09 study design was revised to strengthen analyses and better support planning for a potential registrational trial, which could improve the quality of pivotal data for approval decisions.
Bears Say
Clinical Readout DelayTopline results for the ASPEN-09 study were postponed, delaying a key clinical-readout catalyst and extending uncertainty about the drug's efficacy profile.
Near-term Data FlowThe planned interim data update will not occur, removing a near-term information milestone and reducing visibility into treatment performance for market participants.
Timeline And Partner Execution RiskPostponement of ASPEN-09 readouts increases uncertainty around timing for registrational planning and could complicate coordination with partner studies and expectations.
ALX Oncology Holdings News
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.40 and its highest was $2.66 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $211.26M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 58 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on May 08, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.018.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.14.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 134,562,910 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 11.23%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ALX Oncology Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.75 (184.43% Upside)
$4.75 (184.43% Upside)
Hedge Fund Trend
Increased
By 23.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.66%
12-Months-Change
Fundamentals
Return on Equity
-124.06%
Trailing 12-Months
Asset Growth
47.50%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology firm focused on developing innovative therapies for cancer patients. At the forefront of its pipeline is ALX148, a CD47 blocking therapeutic, which is progressing through Phase 1b/2 clinical trials. This candidate is being evaluated for a variety of hematologic malignancies, including myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin's lymphoma. Additionally, it targets a range of solid tumors, such as head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumor indications. Beyond its lead candidate, ALX Oncology's pre-clinical portfolio includes ALTA-002, a SIRPa TRAAC designed to engage both the innate and adaptive immune systems in the fight against cancer. The company maintains a robust network of strategic collaborations, including a Phase 2 trial with Merck evaluating ALX148 in combination with pembrolizumab (with or without chemotherapy) for head and neck cancer. Another partnership involves Zymeworks for a Phase 1 trial assessing ALX148 alongside the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors. Furthermore, ALX Oncology collaborates with Tallac Therapeutics for the development, manufacturing, and commercialization of a novel class of cancer immunotherapeutics. Further bolstering its capabilities are licensing agreements with Selexis SA and Crystal Bioscience, Inc. Founded in 2015, the company operates from its headquarters in South San Francisco, California.
ALXO Company Deck
ALXO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful, reproducible efficacy signals for evorpacept combinations—especially in CD47-high, centrally confirmed HER2-positive patients—with durable responses across independent studies, a large evorpacept safety database, progressing second program (ALX2004), and strengthened corporate resources. However, the clinical findings are preliminary given small exploratory cohorts, CD47 assay/cutoff uncertainty, discordant HER2 testing, and anticipated need for a registrational trial, which introduces execution and regulatory risk. Overall, momentum and positive clinical signals outweigh the limitations, but important validation and prospective biomarker work remain.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$4.75
▲(184.43% Upside)
Technical Analysis
Ownership Overview
10.06% Insiders
3.58% Mutual Funds
55.50% Other Institutional Investors
27.76% Public Companies and
Individual Investors